| Authors: |
Madrid M; Cellino Biotech, Cambridge, USA., Lakshmipathy U; Pharma Services, Thermo Fisher Scientific, Carlsbad, USA., Zhang X; Aspen Neuroscience Inc., San Diego, USA., Bharti K; National Eye Institute of the National Institutes of Health, Bethesda, USA., Wall DM; Peter MacCallum Cancer Centre, Melbourne Australia; Cell Therapies Pty Ltd, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Sato Y; National Institute of Health Sciences, Kawasaki, Japan., Muschler G; Cleveland Clinic, Cleveland, USA., Ting A; BRL C> consulting, LLC., Cleveland, USA., Smith N; Cell Therapies Pty Ltd, Melbourne, Australia., Deguchi S; CIRA Foundation, Facility for iPS Cell Therapy (FiT), Kyoto, Japan., Kawamata S; Cyto-Facto Inc., Kobe, Japan; Kobe University, Kobe, Japan. Electronic address: kawamata.shin@cytofacto.com., Moore JC; Sampled, New York City, USA., Makovoz B; Cellino Biotech, Cambridge, USA., Sullivan S; iPSirius, Paris, France; Lindville Bio, London, UK., Falco V; Lindville Bio, London, UK., Al-Riyami AZ; Department of Hematology, Sultan Qaboos University Hospital, University Medical City, Muscat, Oman. |
